Eli Lilly's Omvoh Secures USFDA Approval
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved a single-injection, once-monthly maintenance regimen of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).
"In clinical practice, we see that simplifying maintenance treatment can make a difference in the overall patient experience," said Miguel Regueiro, M.D., board-certified gastroenterologist specializing in inflammatory bowel disease. "A single monthly injection of Omvoh gives patients a regimen that's easier to manage alongside the unpredictability of living with ulcerative colitis."
The Omvoh single-injection, citrate-free maintenance dose will be available in the U.S. via prefilled pen or prefilled syringe in early 2026.
Author's summary: Eli Lilly's Omvoh gets FDA approval.
More News
- NYC Selects Rybak as Developer for Coney Island Housing Project
- Pediatric Brain Tumor Foundation Selects Bublup to Power Family Support Communities and Resource-Sharing Platform
- The Angel Ball Honors Tina Knowles
- Mercor Capitalizes on Industry Upheaval, Reaches $10 Billion Valuation with $350 Million Funding Surge
- Tomago Aluminium is more than just a smelter, it's a strategic asset
- TikTok U.S. Creator Summit: Three new features announced today - 9to5Mac
- Travel-Ready Base Layers That Simplify Packing